Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01346163 · ClinicalTrials.gov registry record · Phase 1
Add On Treatment for Cognitive Deficits in Schizophrenia
A Phase 1 study of Schizophrenia, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT01346163: Completed Phase 1 study of Schizophrenia, sponsored by University of Pennsylvania.
NCT01346163 is a Phase 1 study of Schizophrenia that has completed, run by University of Pennsylvania. The registered enrollment target is 16 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01346163, a Phase 1 study of Schizophrenia, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will look at the impact of dosing as well as ongoing treatment with an investigation medication identified as PF-03654746, on cognitive and physiologic indicators of brain function. Data from this study will assist with the evaluation of the utility of functional magnetic resonance imaging, arterial spin labeling (ASL), and electrophysiologic measures in the detection of early signals of the effectiveness of medications developed to target cognitive impairment in schizophrenia. Safety and tolerability of PF-03654746 in this population will be also be evaluated.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG PF 03654746
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
What the finished NCT01346163 record still lists
NCT01346163 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01346163 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01346163 about?
NCT01346163 is a clinical study titled "Add On Treatment for Cognitive Deficits in Schizophrenia". This study will look at the impact of dosing as well as ongoing treatment with an investigation medication identified as PF-03654746, on cognitive and physiologic indicators of brain function. Data from this study will assist with the evaluation of the utility of functional magnetic resonance imagin...
What is the current status of trial NCT01346163?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-04. Estimated completion is 2010-11.
What conditions does trial NCT01346163 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT01346163?
The interventions under investigation include: Placebo (OTHER), PF 03654746 (DRUG).
Who is sponsoring clinical trial NCT01346163?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01346163 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01346163's enrollment target sits among peer trials
16 297th of 315 higher than 16 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia